DiaMedica Therapeutics (NASDAQ:DMAC) Shares Down 3.6%

Shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) fell 3.6% during trading on Tuesday . The company traded as low as $2.41 and last traded at $2.42. 5,238 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 41,772 shares. The stock had previously closed at $2.51.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on DMAC shares. Oppenheimer restated an “outperform” rating and set a $6.00 price objective (down previously from $7.00) on shares of DiaMedica Therapeutics in a research report on Thursday, March 21st. Craig Hallum reduced their target price on DiaMedica Therapeutics from $11.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, March 21st.

DiaMedica Therapeutics Stock Performance

The company has a market cap of $91.86 million, a P/E ratio of -3.90 and a beta of 1.69. The stock has a 50-day moving average of $2.81 and a two-hundred day moving average of $2.70.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its quarterly earnings data on Wednesday, March 20th. The company reported ($0.14) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.14). As a group, sell-side analysts forecast that DiaMedica Therapeutics Inc. will post -0.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Avantax Advisory Services Inc. bought a new position in shares of DiaMedica Therapeutics in the fourth quarter worth approximately $36,000. Stonebridge Capital Advisors LLC purchased a new stake in DiaMedica Therapeutics during the 3rd quarter valued at $52,000. Finally, Paragon Associates & Paragon Associates II Joint Venture grew its holdings in DiaMedica Therapeutics by 6.4% in the 4th quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 500,000 shares of the company’s stock worth $1,420,000 after acquiring an additional 30,000 shares during the last quarter. Hedge funds and other institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.